Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor

Sound's for hearing loss: Co's drug wins FDA breakthrough tag for Meniere’s disease

Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss

Belite Bio reports landmark phase 3 success for Stargardt Disease therapy

Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders

Otsuka files FDA application for first-in-class ADHD drug

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio

The formulation is backed by over 80 clinical trials and 200 scientific publications

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases